Bioventus Inc
For the period ended Sep 28, 2024. Filed Nov 5, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 28, 2024 · Filed Nov 5, 2024
BVS$11.18+1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Condensed Statements of Cash Flows for the
Consolidated Condensed Statements of Cash Flows
Nine Months Ended September 28, 2024 and September 30, 2023
(Amounts in thousands)
| Nine Months Ended | ||
|---|---|---|
| September 28, 2024 | September 30, 2023 | |
| Operating activities: | ||
| Net loss | $(43,515) | $(187,969) |
| Less: Loss from discontinued operations, net of tax | — | (74,429) |
| Loss from continuing operations | (43,515) | (113,540) |
| Adjustments to reconcile net loss to net cash from operating activities: | ||
| Depreciation and amortization | 37,150 | 44,900 |
| Benefit for expected credit losses | (613) | (695) |
| Equity-based compensation | 8,327 | 947 |
| Change in fair value of contingent consideration | 1,078 | 429 |
| Deferred income taxes | (8,609) | (3,540) |
| Impairment of assets | 33,901 | 78,615 |
| Loss on disposals | — | 2,381 |
| Unrealized loss on foreign currency fluctuations | (133) | 1,397 |
| Other, net | 1,559 | 1,401 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (4,874) | 19,247 |
| Inventories | (10,874) | (14,123) |
| Accounts payable and accrued expenses | 1,224 | (11,067) |
| Other current and noncurrent assets and liabilities | 4,852 | 787 |
| Net cash from operating activities - continuing operations | 19,473 | 7,139 |
| Net cash from operating activities - discontinued operations | — | (2,169) |
| Net cash from operating activities | 19,473 | 4,970 |
| Investing activities: | ||
| Proceeds from sale of a business | — | 34,897 |
| Purchase of property and equipment | (432) | (6,993) |
| Investments and acquisition of distribution rights | (709) | — |
| Net cash from investing activities - continuing operations | (1,141) | 27,904 |
| Net cash from investing activities - discontinued operations | — | (11,506) |
| Net cash from investing activities | (1,141) | 16,398 |
| Financing activities: | ||
| Proceeds from issuance of Class A common stock | 1,339 | 620 |
| Borrowing on revolver | — | 64,000 |
| Payment on revolver | — | (49,000) |
| Debt refinancing costs | (1,180) | (3,661) |
| Payments on long-term debt | (11,320) | (38,264) |
| Other, net | (564) | (334) |
| Net cash from financing activities | (11,725) | (26,639) |
| Effect of exchange rate changes on cash | (497) | 261 |
| Net change in cash, cash equivalents and restricted cash | 6,110 | (5,010) |
| Cash, cash equivalents and restricted cash at the beginning of the period | 36,964 | 31,837 |
| Cash, cash equivalents and restricted cash at the end of the period | $43,074 | $26,827 |
| Supplemental disclosure of noncash investing and financing activities | ||
| Accrued liabilities for intellectual property | $— | $709 |
| Accounts payable for purchase of property, plant and equipment | $113 | $1,304 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.